Skip to main content
CJ Bioscience logo

CJ Bioscience — Investor Relations & Filings

Ticker · 311690 ISIN · KR7311690002 KO Professional, scientific and technical activities
Open in API
Filings indexed 209 across all filing types
Latest filing 2021-07-28 Major Shareholding Noti…
Country KR South Korea
Listing KO 311690

About CJ Bioscience

https://www.cjbioscience.com/en/

CJ Bioscience is a company focused on developing microbiome-based therapeutics to address unmet medical needs. It utilizes a proprietary AI-powered drug discovery platform, Ez-Mx®, to identify and advance novel live biotherapeutic products (LBPs). The company's primary focus is on creating treatments for complex diseases, with a pipeline targeting oncology and inflammatory bowel disease (IBD). Key candidates include CJRB-101, its lead oncology asset, and CJRB-201, a promising oral therapeutic for IBD that has demonstrated significant anti-inflammatory efficacy in preclinical models. In addition to its drug development programs, CJ Bioscience provides next-generation sequencing (NGS) and bioinformatics solutions to the global research community through its EzBioCloud platform.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity acquires a significant stake (typically 5% or more) in a company, often with the intent to influence management. This falls under the 'Major Shareholding Notification' category.
2021-07-28 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from a Korean company (ChunLab) detailing a decision for a third-party capital increase (유상증자결정). This type of filing is a regulatory requirement in South Korea for significant corporate events such as capital structure changes, share issuance, and changes in major shareholders. It fits the definition of a 'Share Issue/Capital Change' (SHA) as it details the issuance of new shares to a third party (CJ CheilJedang) and the associated capital increase.
2021-07-21 Korean
최대주주변경을수반하는주식양수도계약체결
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing detailing a 'Change in Largest Shareholder' due to a stock purchase agreement (M&A activity). It outlines the transfer of shares from existing shareholders to CJ CheilJedang Corporation, including the contract date, share quantities, and financial terms. While it involves M&A-related activity, it is specifically a disclosure of a change in control/shareholding structure, which falls under the category of M&A activity (TAR) as it relates to a takeover/acquisition bid.
2021-07-21 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. It details specific amendments made to sections such as dividend policy, articles of incorporation, research and development activities, and financial data. Since it is a formal regulatory filing amending a comprehensive annual report, it falls under the category of a regulatory filing or an amendment to an annual report. Given the specific structure and the nature of the document as a formal correction to a 10-K equivalent, it is classified as a 10-K (Annual Report) amendment. FY 2020
2021-06-25 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. It does not fit into categories like Annual Reports, Earnings Releases, or M&A. It is specifically a 'Capital/Financing Update' as it details the change in conversion price and the resulting change in the number of convertible shares.
2021-06-02 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'ChunLab' covering the period from 2021-01-01 to 2021-03-31. It contains detailed corporate information, capital changes, shareholding structure, and business descriptions, which are characteristic of a formal interim/quarterly financial report filed with the Korean financial authorities (FSS/KRX). Q1 2021
2021-05-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.